Axsome Therapeutics (AXSM) EPS (Weighted Average and Diluted) (2020 - 2026)
Axsome Therapeutics' (AXSM) quarterly EPS (Weighted Average and Diluted) came in at -$1.26 in Q1 2026, down 3.28% year-on-year from -$1.3 in Q1 2025, and down 129.09% quarter-over-quarter from -$0.55 in Q4 2025.
Axsome Therapeutics (AXSM) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Axsome Therapeutics has disclosed EPS (Weighted Average and Diluted) across 7 years of filings, most recently posting -$1.26 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$1.26, down 3.28% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.72 (up 35.53% YoY), and the FY2025 annual result was -$3.68, up 38.56% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$1.26 for Q1 2026 at Axsome Therapeutics, down from -$0.55 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.26 in Q1 2023 to a low of -$2.13 in Q4 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is -$1.26 (2026), against an average of -$1.22.
- Across the five-year window, EPS (Weighted Average and Diluted) surged 75.47% in 2023 and sank 453.85% in 2024, its largest moves.
- Axsome Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.43 in 2022, then plunged by 48.95% to -$2.13 in 2023, then climbed by 27.7% to -$1.54 in 2024, then jumped by 64.29% to -$0.55 in 2025, then sank by 129.09% to -$1.26 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$1.26 (Q1 2026), -$0.55 (Q4 2025), and -$0.94 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Axsome Therapeutics | 12.84 Bn | 12.54 Bn | 176.48 Mn | -1.26 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.26 |
| Dec 31, 2025 | -0.55 |
| Sep 30, 2025 | -0.94 |
| Jun 30, 2025 | -0.97 |
| Mar 31, 2025 | -1.22 |
| Dec 31, 2024 | -1.54 |
| Sep 30, 2024 | -1.34 |
| Jun 30, 2024 | -1.67 |
| Mar 31, 2024 | -1.44 |
| Dec 31, 2023 | -2.13 |
| Sep 30, 2023 | -1.32 |
| Jun 30, 2023 | -1.54 |
| Mar 31, 2023 | -0.26 |
| Dec 31, 2022 | -1.43 |
| Sep 30, 2022 | -1.07 |
| Jun 30, 2022 | -1.06 |
| Mar 31, 2022 | -1.06 |
| Dec 31, 2021 | -0.90 |
| Sep 30, 2021 | -0.93 |
| Jun 30, 2021 | -0.86 |